BMC Pharmacology and Toxicology· 2026Q2
Epinephrine-mediated sensitization of thioredoxin 1 enhances chlorpromazine protection against acute hepatotoxicity
- 0citations
- Q2SCImago
- 2026year
Short summary
Epinephrine (EP) boosts thioredoxin-1 (Trx1) expression, significantly enhancing chlorpromazine's (CPZ) protective effect against drug-induced acute liver injury (ALI) in mice.
AI-generated from the title and abstract; the full text is not read.
Key points
- Epinephrine (EP) administration increased liver expression of Trx1, TrxL1, and TrxR1.
- EP pre-treatment significantly enhanced chlorpromazine's (CPZ) protective effect against acetaminophen-induced acute liver injury (ALI) in mice.
- The combined treatment led to improved liver biomarkers, reduced inflammation, and attenuated oxidative stress.
- Molecular analysis in hepatoma cells revealed EP-induced thioredoxin system activation correlated with β-arrestin1, TrxL1, and CREB1 overexpression.
AI-generated from the title and abstract; the full text is not read.
Abstract
Acute liver injury (ALI) is characterised by rapid hepatic necrosis and compromised liver functions. Drug-induced ALI, in particular, is associated with glutathione depletion and overproduction of reactive oxygen species (ROS). These alterations highlight the contribution of the thioredoxin system (Trx/TrxR/NADPH) in preserving hepatic redox homeostasis. Previously, we demonstrated that thioredoxin-1 (Trx1) overexpression exerts protective effects against ischemic heart and peripheral vascular disease. Also, the neuroprotective role of thioredoxin reductase (TrxR1) has been reported in Parkinson’s Disease. However, it remains unclear whether epinephrine (EP)-mediated boosting of the thioredoxin system, together with chlorpromazine (CPZ), provides sufficient protection against drug-induced ALI. To investigate this hypothesis, C57BL/6 mice were chronically administered a low dose of EP to enhance the expression of Trx1/TrxR1, followed by ALI induction with N-acetyl-para-aminophenol (APAP) and treatment with a subtoxic dose of CPZ. In parallel, hepatoma cell lines were treated with EP and/or CPZ to monitor the associated subcellular and molecular changes. The results showed that EP enhanced the expression of Trx1, thioredoxin-like protein 1 (TrxL1), and TrxR1 in liver and TrxR1 in hepatoma cell lines. Also, EP attenuated liver injury and enhanced the therapeutic effect of CPZ in ALI mice. A significant improvement in liver biomarkers, resolution of inflammation, attenuated oxidative stress, and restoration of hepatic histological architecture accompanied these observations. Moreover, activation of the thioredoxin system in hepatoma cells was associated with overexpression of β-arrestin1, TrxL1, and cAMP-response element-binding protein (CREB1), mirroring their involvement in Trx-mediated protection. Conclusively, these results addressed the protective role of boosting the cytosolic thioredoxin system in drug-induced ALI.
The authors' abstract, as published at the source. BMC Pharmacology and Toxicology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmacology (Pharmacology, Toxicology and Pharmaceutics)
PharmacologyPharmacology, Toxicology and Pharmaceutics